AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. ADVM
  4. [Form 4] Adverum Biotechnologies, Inc. Insider Trading Activity

[Form 4] Adverum Biotechnologies, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Linda M. Rubinstein, Chief Financial Officer of Adverum Biotechnologies (ADVM), reported modifications to stock options following the company's reverse stock split effective March 21, 2024. The reverse split combined every ten shares into one share, with corresponding adjustments to stock options.

Key transactions on June 17, 2025:

  • Cancellation and replacement of 85,000 stock options originally granted on August 3, 2023, with exercise price adjusted from $21 to $10.14
  • Cancellation and replacement of 35,000 stock options originally granted on February 12, 2024, with exercise price adjusted from $19.90 to $10.14

The vesting schedules remain unchanged: the first grant vests 25% after six months with monthly vesting thereafter until August 3, 2026, while the second grant vests 25% after one year with monthly vesting until February 12, 2028, subject to continued service.

Linda M. Rubinstein, Chief Financial Officer di Adverum Biotechnologies (ADVM), ha comunicato modifiche alle opzioni su azioni a seguito dello split azionario inverso della societ脿, efficace dal 21 marzo 2024. Lo split ha unito ogni dieci azioni in una sola, con conseguenti aggiustamenti delle opzioni su azioni.

Operazioni principali del 17 giugno 2025:

  • Annullamento e sostituzione di 85.000 opzioni su azioni originariamente concesse il 3 agosto 2023, con prezzo di esercizio adeguato da 21$ a 10,14$
  • Annullamento e sostituzione di 35.000 opzioni su azioni originariamente concesse il 12 febbraio 2024, con prezzo di esercizio adeguato da 19,90$ a 10,14$

I piani di maturazione rimangono invariati: la prima concessione matura il 25% dopo sei mesi con maturazione mensile fino al 3 agosto 2026, mentre la seconda matura il 25% dopo un anno con maturazione mensile fino al 12 febbraio 2028, subordinata alla continuit脿 del servizio.

Linda M. Rubinstein, Directora Financiera de Adverum Biotechnologies (ADVM), inform贸 modificaciones en las opciones sobre acciones tras la divisi贸n inversa de acciones de la compa帽铆a, vigente desde el 21 de marzo de 2024. La divisi贸n combin贸 cada diez acciones en una sola, con ajustes correspondientes en las opciones sobre acciones.

Transacciones clave del 17 de junio de 2025:

  • Cancelaci贸n y reemplazo de 85,000 opciones sobre acciones otorgadas originalmente el 3 de agosto de 2023, con precio de ejercicio ajustado de $21 a $10.14
  • Cancelaci贸n y reemplazo de 35,000 opciones sobre acciones otorgadas originalmente el 12 de febrero de 2024, con precio de ejercicio ajustado de $19.90 a $10.14

Los calendarios de adquisici贸n permanecen sin cambios: la primera concesi贸n adquiere el 25% despu茅s de seis meses con adquisici贸n mensual hasta el 3 de agosto de 2026, mientras que la segunda adquiere el 25% despu茅s de un a帽o con adquisici贸n mensual hasta el 12 de febrero de 2028, sujeto a la continuidad del servicio.

Linda M. Rubinstein, Adverum Biotechnologies(ADVM)鞚� 斓滉碃鞛毂呾瀯鞛�(CFO)電� 2024雲� 3鞗� 21鞚茧秬韯� 鞁滍枆霅� 須岇偓鞚� 欤检嫕 鞐硲頃╈棎 霐半ジ 鞀ろ啞鞓奠厴 氤�瓴� 靷暛鞚� 氤搓碃頄堨姷雼堧嫟. 鞐硲頃╈潃 10欤茧ゼ 1欤茧 頃╇硲頃橂┌, 鞚挫棎 霐半澕 鞀ろ啞鞓奠厴霃� 臁办爼霅橃棃鞀惦媹雼�.

2025雲� 6鞗� 17鞚� 欤检殧 瓯半灅 雮挫毄:

  • 2023雲� 8鞗� 3鞚检棎 攵�鞐悳 85,000臧滌潣 鞀ろ啞鞓奠厴 旆唽 氚� 甑愳泊, 頄夓偓臧�瓴╈澊 $21鞐愳劀 $10.14搿� 臁办爼霅�
  • 2024雲� 2鞗� 12鞚检棎 攵�鞐悳 35,000臧滌潣 鞀ろ啞鞓奠厴 旆唽 氚� 甑愳泊, 頄夓偓臧�瓴╈澊 $19.90鞐愳劀 $10.14搿� 臁办爼霅�

氩犾姢韺� 鞚检爼鞚� 氤�瓴诫悩歆� 鞎婌晿鞀惦媹雼�: 觳� 氩堨Ц 攵�鞐姅 6臧滌洈 頉� 25% 氩犾姢韺呺悩氅� 鞚错泟 毵れ洈 氩犾姢韺呺悩鞏� 2026雲� 8鞗� 3鞚缄箤歆� 歆勴枆霅橁碃, 霊� 氩堨Ц 攵�鞐姅 1雲� 頉� 25% 氩犾姢韺呺悩氅� 毵れ洈 氩犾姢韺呺悩鞏� 2028雲� 2鞗� 12鞚缄箤歆� 瓿勳啀 攴茧 臁瓣贝 頃橃棎 歆勴枆霅╇媹雼�.

Linda M. Rubinstein, Directrice Financi猫re d'Adverum Biotechnologies (ADVM), a annonc茅 des modifications des options d'achat d'actions suite au regroupement d'actions invers茅 de la soci茅t茅 effectif au 21 mars 2024. Ce regroupement a combin茅 dix actions en une seule, avec des ajustements correspondants des options d'achat.

Transactions cl茅s du 17 juin 2025 :

  • Annulation et remplacement de 85 000 options d'achat d'actions initialement attribu茅es le 3 ao没t 2023, avec un prix d'exercice ajust茅 de 21 $ 脿 10,14 $
  • Annulation et remplacement de 35 000 options d'achat d'actions initialement attribu茅es le 12 f茅vrier 2024, avec un prix d'exercice ajust茅 de 19,90 $ 脿 10,14 $

Les calendriers d'acquisition restent inchang茅s : la premi猫re attribution acquiert 25 % apr猫s six mois avec une acquisition mensuelle jusqu'au 3 ao没t 2026, tandis que la seconde acquiert 25 % apr猫s un an avec une acquisition mensuelle jusqu'au 12 f茅vrier 2028, sous r茅serve de la poursuite du service.

Linda M. Rubinstein, Chief Financial Officer von Adverum Biotechnologies (ADVM), berichtete 眉ber 脛nderungen bei Aktienoptionen infolge des Reverse Stock Splits des Unternehmens, der am 21. M盲rz 2024 wirksam wurde. Der Reverse Split fasste jeweils zehn Aktien zu einer zusammen, wobei die Aktienoptionen entsprechend angepasst wurden.

Wichtige Transaktionen am 17. Juni 2025:

  • Stornierung und Ersatz von 85.000 Aktienoptionen, die urspr眉nglich am 3. August 2023 gew盲hrt wurden, mit einer Anpassung des Aus眉bungspreises von 21 $ auf 10,14 $
  • Stornierung und Ersatz von 35.000 Aktienoptionen, die urspr眉nglich am 12. Februar 2024 gew盲hrt wurden, mit einer Anpassung des Aus眉bungspreises von 19,90 $ auf 10,14 $

Die Vesting-Pl盲ne bleiben unver盲ndert: Die erste Zuteilung vestet 25 % nach sechs Monaten mit monatlicher Vesting bis zum 3. August 2026, die zweite Zuteilung vestet 25 % nach einem Jahr mit monatlicher Vesting bis zum 12. Februar 2028, jeweils vorbehaltlich fortgesetzter Dienstzeit.

Positive
  • None.
Negative
  • None.

Linda M. Rubinstein, Chief Financial Officer di Adverum Biotechnologies (ADVM), ha comunicato modifiche alle opzioni su azioni a seguito dello split azionario inverso della societ脿, efficace dal 21 marzo 2024. Lo split ha unito ogni dieci azioni in una sola, con conseguenti aggiustamenti delle opzioni su azioni.

Operazioni principali del 17 giugno 2025:

  • Annullamento e sostituzione di 85.000 opzioni su azioni originariamente concesse il 3 agosto 2023, con prezzo di esercizio adeguato da 21$ a 10,14$
  • Annullamento e sostituzione di 35.000 opzioni su azioni originariamente concesse il 12 febbraio 2024, con prezzo di esercizio adeguato da 19,90$ a 10,14$

I piani di maturazione rimangono invariati: la prima concessione matura il 25% dopo sei mesi con maturazione mensile fino al 3 agosto 2026, mentre la seconda matura il 25% dopo un anno con maturazione mensile fino al 12 febbraio 2028, subordinata alla continuit脿 del servizio.

Linda M. Rubinstein, Directora Financiera de Adverum Biotechnologies (ADVM), inform贸 modificaciones en las opciones sobre acciones tras la divisi贸n inversa de acciones de la compa帽铆a, vigente desde el 21 de marzo de 2024. La divisi贸n combin贸 cada diez acciones en una sola, con ajustes correspondientes en las opciones sobre acciones.

Transacciones clave del 17 de junio de 2025:

  • Cancelaci贸n y reemplazo de 85,000 opciones sobre acciones otorgadas originalmente el 3 de agosto de 2023, con precio de ejercicio ajustado de $21 a $10.14
  • Cancelaci贸n y reemplazo de 35,000 opciones sobre acciones otorgadas originalmente el 12 de febrero de 2024, con precio de ejercicio ajustado de $19.90 a $10.14

Los calendarios de adquisici贸n permanecen sin cambios: la primera concesi贸n adquiere el 25% despu茅s de seis meses con adquisici贸n mensual hasta el 3 de agosto de 2026, mientras que la segunda adquiere el 25% despu茅s de un a帽o con adquisici贸n mensual hasta el 12 de febrero de 2028, sujeto a la continuidad del servicio.

Linda M. Rubinstein, Adverum Biotechnologies(ADVM)鞚� 斓滉碃鞛毂呾瀯鞛�(CFO)電� 2024雲� 3鞗� 21鞚茧秬韯� 鞁滍枆霅� 須岇偓鞚� 欤检嫕 鞐硲頃╈棎 霐半ジ 鞀ろ啞鞓奠厴 氤�瓴� 靷暛鞚� 氤搓碃頄堨姷雼堧嫟. 鞐硲頃╈潃 10欤茧ゼ 1欤茧 頃╇硲頃橂┌, 鞚挫棎 霐半澕 鞀ろ啞鞓奠厴霃� 臁办爼霅橃棃鞀惦媹雼�.

2025雲� 6鞗� 17鞚� 欤检殧 瓯半灅 雮挫毄:

  • 2023雲� 8鞗� 3鞚检棎 攵�鞐悳 85,000臧滌潣 鞀ろ啞鞓奠厴 旆唽 氚� 甑愳泊, 頄夓偓臧�瓴╈澊 $21鞐愳劀 $10.14搿� 臁办爼霅�
  • 2024雲� 2鞗� 12鞚检棎 攵�鞐悳 35,000臧滌潣 鞀ろ啞鞓奠厴 旆唽 氚� 甑愳泊, 頄夓偓臧�瓴╈澊 $19.90鞐愳劀 $10.14搿� 臁办爼霅�

氩犾姢韺� 鞚检爼鞚� 氤�瓴诫悩歆� 鞎婌晿鞀惦媹雼�: 觳� 氩堨Ц 攵�鞐姅 6臧滌洈 頉� 25% 氩犾姢韺呺悩氅� 鞚错泟 毵れ洈 氩犾姢韺呺悩鞏� 2026雲� 8鞗� 3鞚缄箤歆� 歆勴枆霅橁碃, 霊� 氩堨Ц 攵�鞐姅 1雲� 頉� 25% 氩犾姢韺呺悩氅� 毵れ洈 氩犾姢韺呺悩鞏� 2028雲� 2鞗� 12鞚缄箤歆� 瓿勳啀 攴茧 臁瓣贝 頃橃棎 歆勴枆霅╇媹雼�.

Linda M. Rubinstein, Directrice Financi猫re d'Adverum Biotechnologies (ADVM), a annonc茅 des modifications des options d'achat d'actions suite au regroupement d'actions invers茅 de la soci茅t茅 effectif au 21 mars 2024. Ce regroupement a combin茅 dix actions en une seule, avec des ajustements correspondants des options d'achat.

Transactions cl茅s du 17 juin 2025 :

  • Annulation et remplacement de 85 000 options d'achat d'actions initialement attribu茅es le 3 ao没t 2023, avec un prix d'exercice ajust茅 de 21 $ 脿 10,14 $
  • Annulation et remplacement de 35 000 options d'achat d'actions initialement attribu茅es le 12 f茅vrier 2024, avec un prix d'exercice ajust茅 de 19,90 $ 脿 10,14 $

Les calendriers d'acquisition restent inchang茅s : la premi猫re attribution acquiert 25 % apr猫s six mois avec une acquisition mensuelle jusqu'au 3 ao没t 2026, tandis que la seconde acquiert 25 % apr猫s un an avec une acquisition mensuelle jusqu'au 12 f茅vrier 2028, sous r茅serve de la poursuite du service.

Linda M. Rubinstein, Chief Financial Officer von Adverum Biotechnologies (ADVM), berichtete 眉ber 脛nderungen bei Aktienoptionen infolge des Reverse Stock Splits des Unternehmens, der am 21. M盲rz 2024 wirksam wurde. Der Reverse Split fasste jeweils zehn Aktien zu einer zusammen, wobei die Aktienoptionen entsprechend angepasst wurden.

Wichtige Transaktionen am 17. Juni 2025:

  • Stornierung und Ersatz von 85.000 Aktienoptionen, die urspr眉nglich am 3. August 2023 gew盲hrt wurden, mit einer Anpassung des Aus眉bungspreises von 21 $ auf 10,14 $
  • Stornierung und Ersatz von 35.000 Aktienoptionen, die urspr眉nglich am 12. Februar 2024 gew盲hrt wurden, mit einer Anpassung des Aus眉bungspreises von 19,90 $ auf 10,14 $

Die Vesting-Pl盲ne bleiben unver盲ndert: Die erste Zuteilung vestet 25 % nach sechs Monaten mit monatlicher Vesting bis zum 3. August 2026, die zweite Zuteilung vestet 25 % nach einem Jahr mit monatlicher Vesting bis zum 12. Februar 2028, jeweils vorbehaltlich fortgesetzter Dienstzeit.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rubinstein Linda M
(Last) (First) (Middle)
C/O ADVERUM BIOTECHNOLOGIES, INC.
100 CARDINAL WAY
(Street)
REDWOOD CITY CA 94063
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Adverum Biotechnologies, Inc. [ ADVM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF FINANCIAL OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $21(1) 06/17/2025 D(2) 85,000(1) (3) 08/02/2033 Common Stock 85,000(1) $0 0 D
Stock Option (Right to Buy) $10.14 06/17/2025 A(2) 85,000(1) (3) 08/02/2033 Common Stock 85,000(1) $0 85,000(1) D
Stock Option (Right to Buy) $19.9(1) 06/17/2025 D(4) 35,000(1) (5) 02/11/2034 Common Stock 35,000(1) $0 0 D
Stock Option (Right to Buy) $10.14 06/17/2025 A(4) 35,000(1) (5) 02/11/2034 Common Stock 35,000(1) $0 35,000(1) D
Explanation of Responses:
1. Effective March 21, 2024, the Issuer effected a reverse stock split (the "Reverse Split") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten.
2. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on August 3, 2023.
3. Twenty-five percent (25%) of the total number of shares subject to the option vested and became exercisable on the six month anniversary of August 3, 2023, and 1/36 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of August 3, 2026, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date.
4. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on February 12, 2024.
5. Twenty-five percent (25%) of the total number of shares subject to the option vested and became exercisable on the first anniversary of February 12, 2024, and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of February 12, 2028, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date.
/s/ Aneta Fergson, Attorney-in-Fact 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What changes were made to Linda Rubinstein's stock options at ADVM on June 17, 2025?

On June 17, 2025, Linda Rubinstein, ADVM's CFO, had her stock options repriced. Two sets of options were modified: 85,000 shares were repriced from $21 to $10.14 (originally granted August 3, 2023), and 35,000 shares were repriced from $19.90 to $10.14 (originally granted February 12, 2024). The expiration dates remained unchanged at August 2, 2033 and February 11, 2034 respectively.

How many ADVM stock options does Linda Rubinstein own after the June 2025 repricing?

After the June 2025 repricing, Linda Rubinstein owns a total of 120,000 stock options of ADVM, consisting of 85,000 options at $10.14 expiring August 2, 2033, and 35,000 options at $10.14 expiring February 11, 2034. All options are held directly (not indirectly through other entities).

What is the vesting schedule for ADVM CFO Linda Rubinstein's repriced stock options?

The 85,000 options granted in August 2023 vest 25% after six months (February 2024) with 1/36 monthly thereafter until fully vested on August 3, 2026. The 35,000 options granted in February 2024 vest 25% after one year (February 2025) with 1/48 monthly thereafter until fully vested on February 12, 2028. Both require continuous service with ADVM.

How did ADVM's March 2024 reverse stock split affect Linda Rubinstein's options?

On March 21, 2024, ADVM executed a 1-for-10 reverse stock split where every 10 shares were combined into 1 share. Each stock option was similarly adjusted - options to purchase 10 shares became options to purchase 1 share, and the exercise prices were multiplied by 10 to maintain equivalent value.
Stock ADVM logo
Adverum Biotech

NASDAQ:ADVM

ADVM Rankings

#5272 Ranked by Market Cap
N/A Ranked by Dividends

ADVM Latest News

Aug 12, 2025
Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights
Aug 6, 2025
Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Jun 5, 2025
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 14, 2025
Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights
May 2, 2025
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ADVM Latest SEC Filings

Aug 12, 2025
[10-Q] Adverum Biotechnologies, Inc. Quarterly Earnings Report
Aug 12, 2025
[8-K] Adverum Biotechnologies, Inc. Reports Material Event
Aug 5, 2025
[SCHEDULE 13G/A] Adverum Biotechnologies, Inc. SEC Filing
Jun 20, 2025
[Form 4] Adverum Biotechnologies, Inc. Insider Trading Activity
Jun 20, 2025
[Form 4] Adverum Biotechnologies, Inc. Insider Trading Activity

ADVM Stock Data

46.80M
16.72M
13.1%
79.54%
4.95%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
REDWOOD CITY